NAMS MENOPAUSE EXAM Q-BANK - COMPLETE CERTIFIED
MENOPAUSE PRACTITIONER PRACTICE QUESTIONS WITH
VERIFIED ANSWERS & EXPLANATIONS - UPDATED 2026/2027
STUDY RESOURCE
120 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NAMS MENOPAUSE EXAM Q-BANK - COMPLETE CERTIFIED MENOPAUSE PRACTITIONER PRACTICE
QUESTIONS WITH VERIFIED ANSWERS & EXPLANATIONS - UPDATED 2026/2027 STUDY RESOURCE. It
contains 120 carefully selected questions that reflect the most current exam content and testing strategies. Each
question is accompanied by a correct answer and a detailed rationale that explains the underlying
pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 120 Questions
Foundations - Application - NAMS Menopause Q-bank Complete Certified Menopause Practitioner WITH &
Explanations Updated 2026/2027 Study Resource Menopause Medicine AND Certified Menopause
Practitioner NCMP Preparation Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Foundations OF Menopause 1-20 Woman, History, Hormone, Therapy, Appropriate
AND Perimenopause
Clinical Assessment AND 21-40 Hormone, Therapy, Woman, History, Vasomotor Symptoms
Diagnosis
Hormone Therapy Principles 41-60 Woman, Symptoms, Vasomotor, Therapy, History
AND
Non-hormonal 61-80 Woman, Therapy, History, Vasomotor Symptoms, Estrogen
Pharmacologic Management
Lifestyle AND 81-100 Therapy, Symptoms, Vasomotor, History, Hormone
Complementary Therapies
Management OF Vasomotor 101-120 Woman, Therapy, Hormone, Symptoms, Menopause
Symptoms
TOTAL 120 All questions include answers and detailed rationales
,Section A - Foundations OF Menopause AND
Perimenopause
Q1.
A 52-year-old perimenopausal woman with vasomotor symptoms (VMS) and a history of
hormone receptor-positive breast cancer is seeking relief. Which of the following is the
most appropriate first-line non-hormonal pharmacologic option based on current
evidence?
A. Gabapentin B. Paroxetine
C. Oxybutynin D. Fezolinetant
Correct: D - Fezolinetant
Rationale:Fezolinetant, a neurokinin-3 receptor antagonist, is FDA-approved specifically for
moderate-to-severe VMS and is a safe non-hormonal option for breast cancer survivors.
Paroxetine is contraindicated in tamoxifen users due to CYP2D6 inhibition. Gabapentin and
oxybutynin have off-label use but are less effective or have anticholinergic side effects.
Why the other answers are wrong:
A. Gabapentin is less effective than fezolinetant and has side effects; not first-line.
B. Paroxetine is contraindicated with tamoxifen due to CYP2D6 interaction.
C. Oxybutynin has anticholinergic side effects and is not FDA-approved for VMS.
Reference: NAMS 2022 Position Statement; FEZOLINETANT label 2023
Q2.
Which of the following best describes the change in follicle-stimulating hormone (FSH)
and anti-Müllerian hormone (AMH) levels during the menopausal transition according to
the STRAW+10 staging system?
A. FSH rises and AMH declines in early B. FSH and AMH both decline progressively
transition, with FSH continuing to rise in late throughout the transition.
transition.
C. FSH rises only after the final menstrual D. FSH and AMH levels fluctuate
period, while AMH remains stable until then. unpredictably and are not used for staging.
Correct: A - FSH rises and AMH declines in early transition, with FSH continuing to rise in
late transition.
Rationale:In the STRAW+10 criteria, early menopausal transition (stage -3) is characterized
by elevated FSH and decreased AMH, with FSH continuing to rise and AMH dropping to
undetectable in late transition (stage -2). AMH is a marker of ovarian reserve and declines
before FSH rises.
Page 3
, Section A - Foundations OF Menopause AND Perimenopause
Why the other answers are wrong:
B. AMH declines but FSH rises, not declines.
C. FSH can rise before the final menstrual period, and AMH declines earlier.
D. FSH and AMH are used in staging alongside bleeding patterns.
Reference: Harlow et al. 2012, STRAW+10
Q3.
A postmenopausal woman with a history of venous thromboembolism (VTE) and severe
VMS is considering menopausal hormone therapy (MHT). Which route of estrogen
administration and type of progestogen would be safest to minimize VTE risk?
A. Oral conjugated equine estrogens (CEE) B. Transdermal estradiol with micronized
with medroxyprogesterone acetate (MPA) progesterone
C. Oral estradiol with norethindrone acetate D. Transdermal estradiol with
levonorgestrel-releasing intrauterine system
(LNG-IUS)
Correct: D - Transdermal estradiol with levonorgestrel-releasing intrauterine system
(LNG-IUS)
Rationale:Transdermal estradiol avoids first-pass hepatic metabolism and is associated with
lower VTE risk. The LNG-IUS provides progestogen locally, minimizing systemic progestogen
exposure. Micronized progesterone (option B) is also safer than synthetic progestins but the
LNG-IUS is specifically recommended for women with VTE history.
Why the other answers are wrong:
A. Oral CEE and MPA increase VTE risk, especially in women with prior VTE.
B. Transdermal estradiol and micronized progesterone are safe, but LNG-IUS is preferred for
endometrial protection without systemic progestogen.
C. Oral estradiol and norethindrone acetate carry higher VTE risk than transdermal.
Reference: NAMS 2022; ACOG 2021; Cochrane 2019
Q4.
Which of the following is a key mechanism by which fezolinetant reduces vasomotor
symptoms?
A. Central serotonin reuptake inhibition B. Antagonism of neurokinin-3 receptor in
the hypothalamus
C. Peripheral vasodilation via nitric oxide D. Inhibition of luteinizing hormone secretion
Correct: B - Antagonism of neurokinin-3 receptor in the hypothalamus
Page 4
MENOPAUSE PRACTITIONER PRACTICE QUESTIONS WITH
VERIFIED ANSWERS & EXPLANATIONS - UPDATED 2026/2027
STUDY RESOURCE
120 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NAMS MENOPAUSE EXAM Q-BANK - COMPLETE CERTIFIED MENOPAUSE PRACTITIONER PRACTICE
QUESTIONS WITH VERIFIED ANSWERS & EXPLANATIONS - UPDATED 2026/2027 STUDY RESOURCE. It
contains 120 carefully selected questions that reflect the most current exam content and testing strategies. Each
question is accompanied by a correct answer and a detailed rationale that explains the underlying
pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 120 Questions
Foundations - Application - NAMS Menopause Q-bank Complete Certified Menopause Practitioner WITH &
Explanations Updated 2026/2027 Study Resource Menopause Medicine AND Certified Menopause
Practitioner NCMP Preparation Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Foundations OF Menopause 1-20 Woman, History, Hormone, Therapy, Appropriate
AND Perimenopause
Clinical Assessment AND 21-40 Hormone, Therapy, Woman, History, Vasomotor Symptoms
Diagnosis
Hormone Therapy Principles 41-60 Woman, Symptoms, Vasomotor, Therapy, History
AND
Non-hormonal 61-80 Woman, Therapy, History, Vasomotor Symptoms, Estrogen
Pharmacologic Management
Lifestyle AND 81-100 Therapy, Symptoms, Vasomotor, History, Hormone
Complementary Therapies
Management OF Vasomotor 101-120 Woman, Therapy, Hormone, Symptoms, Menopause
Symptoms
TOTAL 120 All questions include answers and detailed rationales
,Section A - Foundations OF Menopause AND
Perimenopause
Q1.
A 52-year-old perimenopausal woman with vasomotor symptoms (VMS) and a history of
hormone receptor-positive breast cancer is seeking relief. Which of the following is the
most appropriate first-line non-hormonal pharmacologic option based on current
evidence?
A. Gabapentin B. Paroxetine
C. Oxybutynin D. Fezolinetant
Correct: D - Fezolinetant
Rationale:Fezolinetant, a neurokinin-3 receptor antagonist, is FDA-approved specifically for
moderate-to-severe VMS and is a safe non-hormonal option for breast cancer survivors.
Paroxetine is contraindicated in tamoxifen users due to CYP2D6 inhibition. Gabapentin and
oxybutynin have off-label use but are less effective or have anticholinergic side effects.
Why the other answers are wrong:
A. Gabapentin is less effective than fezolinetant and has side effects; not first-line.
B. Paroxetine is contraindicated with tamoxifen due to CYP2D6 interaction.
C. Oxybutynin has anticholinergic side effects and is not FDA-approved for VMS.
Reference: NAMS 2022 Position Statement; FEZOLINETANT label 2023
Q2.
Which of the following best describes the change in follicle-stimulating hormone (FSH)
and anti-Müllerian hormone (AMH) levels during the menopausal transition according to
the STRAW+10 staging system?
A. FSH rises and AMH declines in early B. FSH and AMH both decline progressively
transition, with FSH continuing to rise in late throughout the transition.
transition.
C. FSH rises only after the final menstrual D. FSH and AMH levels fluctuate
period, while AMH remains stable until then. unpredictably and are not used for staging.
Correct: A - FSH rises and AMH declines in early transition, with FSH continuing to rise in
late transition.
Rationale:In the STRAW+10 criteria, early menopausal transition (stage -3) is characterized
by elevated FSH and decreased AMH, with FSH continuing to rise and AMH dropping to
undetectable in late transition (stage -2). AMH is a marker of ovarian reserve and declines
before FSH rises.
Page 3
, Section A - Foundations OF Menopause AND Perimenopause
Why the other answers are wrong:
B. AMH declines but FSH rises, not declines.
C. FSH can rise before the final menstrual period, and AMH declines earlier.
D. FSH and AMH are used in staging alongside bleeding patterns.
Reference: Harlow et al. 2012, STRAW+10
Q3.
A postmenopausal woman with a history of venous thromboembolism (VTE) and severe
VMS is considering menopausal hormone therapy (MHT). Which route of estrogen
administration and type of progestogen would be safest to minimize VTE risk?
A. Oral conjugated equine estrogens (CEE) B. Transdermal estradiol with micronized
with medroxyprogesterone acetate (MPA) progesterone
C. Oral estradiol with norethindrone acetate D. Transdermal estradiol with
levonorgestrel-releasing intrauterine system
(LNG-IUS)
Correct: D - Transdermal estradiol with levonorgestrel-releasing intrauterine system
(LNG-IUS)
Rationale:Transdermal estradiol avoids first-pass hepatic metabolism and is associated with
lower VTE risk. The LNG-IUS provides progestogen locally, minimizing systemic progestogen
exposure. Micronized progesterone (option B) is also safer than synthetic progestins but the
LNG-IUS is specifically recommended for women with VTE history.
Why the other answers are wrong:
A. Oral CEE and MPA increase VTE risk, especially in women with prior VTE.
B. Transdermal estradiol and micronized progesterone are safe, but LNG-IUS is preferred for
endometrial protection without systemic progestogen.
C. Oral estradiol and norethindrone acetate carry higher VTE risk than transdermal.
Reference: NAMS 2022; ACOG 2021; Cochrane 2019
Q4.
Which of the following is a key mechanism by which fezolinetant reduces vasomotor
symptoms?
A. Central serotonin reuptake inhibition B. Antagonism of neurokinin-3 receptor in
the hypothalamus
C. Peripheral vasodilation via nitric oxide D. Inhibition of luteinizing hormone secretion
Correct: B - Antagonism of neurokinin-3 receptor in the hypothalamus
Page 4
